Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700327 | 0.85 | ADRA1D (0.38) | HTR2AHTR2CHTR2BADRA2AADRA2B | |
| SCHEMBL9700351 | 0.83 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9701613 | 0.83 | ADRA2A (0.41) | HTR2AHTR2CADRA2AADRA2BADRA2C | |
| SCHEMBL9699276 | 0.82 | ADRA2A (0.35) | HTR2AHTR2CHTR2BAADATTERT | |
| SCHEMBL9699337 | 0.81 | ADRA2A (0.42) | HTR2AHTR2CADRA2AADRA2BADRA2C | |
| SCHEMBL9728617 | 0.80 | ADRA1A (0.41) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9699287 | 0.77 | HTR7 (0.40) | HTR2CHTR2BADRA2AADRA2BADRA2C | |
| SCHEMBL9699281 | 0.76 | HTR2C (0.37) | HTR2AHTR2CHTR2BADRA2CHTR7 | |
| SCHEMBL10378979 | 0.75 | ADRA1A (0.38) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL9700421 | 0.71 | SMN1; SMN2 (0.38) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5112820-A | Vision defects | STERLING DRUG INC. (US) | 1992-05-12 | — | — | US | disclosed |
| US-5109135-A | 2- or 3-aminomethyl-4-amino-3,4-dihydro-2H-1,4-benzoxazine intermediates | STERLING DRUG INC. (US) | 1992-04-28 | — | — | US | disclosed |
| US-5066803-A | Chemical intermediates for analgesics | STERLING DRUG INC. (US) | 1991-11-19 | — | — | US | disclosed |
| WO-1990007505-A1 | 2- AND 3-AMINOMETHYL-6-ARYLCARBONYL-2,3-DIHYDROPYRROLO[1,2,3-de]-1,4-BENZOXAZINES | STERLING DRUG INC. (US) | 1990-07-12 | — | — | WO | disclosed |
| US-4939138-A | 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |